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Abstract
Background: Establishing clinically relevant animal models of glioblastoma multiforme (GBM)
remains a challenge, and many commonly used cell line-based models do not recapitulate the
invasive growth patterns of patient GBMs. Previously, we have reported the formation of highly
invasive tumour xenografts in nude rats from human GBMs. However, implementing tumour
models based on primary tissue requires that these models can be sufficiently standardised with
consistently high take rates.
Methods: In this work, we collected data on growth kinetics from a material of 29 biopsies
xenografted in nude rats, and characterised this model with an emphasis on neuropathological and
radiological features.
Results: The tumour take rate for xenografted GBM biopsies were 96% and remained close to
100% at subsequent passages in vivo, whereas only one of four lower grade tumours engrafted.
Average time from transplantation to the onset of symptoms was 125 days ± 11.5 SEM.
Histologically, the primary xenografts recapitulated the invasive features of the parent tumours
while endothelial cell proliferations and necrosis were mostly absent. After 4-5 in vivo passages, the
tumours became more vascular with necrotic areas, but also appeared more circumscribed. MRI
typically revealed changes related to tumour growth, several months prior to the onset of
symptoms.
Conclusions: In vivo passaging of patient GBM biopsies produced tumours representative of the
patient tumours, with high take rates and a reproducible disease course. The model provides
combinations of angiogenic and invasive phenotypes and represents a good alternative to in vitro
propagated cell lines for dissecting mechanisms of brain tumour progression.
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Valid model systems are a basic premise for clinical trans-
lation of experimental data. In tumour biology, model
systems typically involve cancer cells that have been pas-
saged numerous times in vitro to provide cancer cell lines
[1]. In animals, the cells are often implanted subcutane-
ously, or in other ectopic locations [2] to produce experi-
mental tumours. The fact that these models are easily
established and standardized, favour their use in high
throughput analyses. Although cell line models provide
highly reproducible results, these findings may have a
limited clinical relevance [3,4]. Notably, only a fraction of
the drug candidates that show promising results in animal
studies is ever implemented in treatment protocols for
cancer patients [5-8]. Thus, more powerful tools than the
models that are currently used are needed.
Orthotopic models are characterised by tumour growth in
the animal, in a site corresponding to the human organ in
which the tumour arises [9-11]. Therefore, such models
provide an optimal system for studying tumour-host
interactions, within an organ-specific niche [12,13].
Moreover, engrafting primary tissue instead of cancer cell
lines may prevent a genetic drift and phenotypic changes
induced by prolonged passaging in vitro [14]. Indeed,
orthotopic tumour models, using primary tissue, have
been established for several cancer subtypes [15-18], and
studies have demonstrated that they can recapitulate
tumour-host interactions and display traits of the parent
tumour [19].
Previously, we established an orthotopic biopsy-based
model to study angiogenesis and malignant progression
[20]. These experiments demonstrated that engraftment
of GBM biopsies produced highly infiltrative gliomas that
could grow in the absence of angiogenesis, and that pas-
saging was accompanied by the onset of angiogenesis and
shorter survival. Thus, the resulting tumours mimicked
essential phenotypic traits of GBMs in patients.
However, experimental tumour models must be repro-
ducible as well as representative. Since orthotopic models
are technically challenging, and since primary tumour tis-
sue display more cellular heterogeneity than cell lines,
their use has been limited. Therefore, data demonstrating
sufficiently high take rates and a reproducible disease
course is needed before we can implement these models
to their full potential. In order to address these issues, we
studied tumour growth in a consecutive series of 29 gli-
oma biopsies used in xenograft implantations. The ani-
mals were scanned using MRI, survival was registered, and
brains were examined. This series also included the
xenograft tumours we previously used to investigate the
invasive and vascular phenotypes in brain tumours [20].
However, the present work also provides experimental
data about the growth parameters, neuropathological and
radiological characteristics of these tumours.
Methods
Tissue culture
Tumour biopsy tissue was obtained from patients at the
neurosurgical department at Haukeland University Hos-
pital, Bergen. The study was approved by the regional Eth-
ical Board at Haukeland University Hospital. Spheroids
were prepared as described previously [14].
Animal experiments
Studies were conducted with 197 male and female
homozygous nude rats (Han:rnu/rnu Rowett) bred and
maintained in an isolation facility in a pathogen free envi-
ronment on a standard 12/12 h day and night cycle. Ani-
mals were fed a standard sterilised pellet diet and
provided sterile tap water ad libitum. The athymic nude rat
is T-cell deficient, but has normal complement and B-cell
function [11]. 10 tumour spheroids (250-350 μm in
diameter) were selected under a light microscope. The ani-
mals were anaesthetized with Hypnorm-Dormicum (0.4
ml/kg) s.c., the head secured in a stereotactic frame
(Benchmark; Neurolab, St Louis, MO) and a short longi-
tudinal incision was made in the scalp exposing the cal-
varium. A burr-hole was made 1 mm posterior to the
bregma and 3 mm to the right of the sagittal suture using
a micro-drill with a bit diameter of 2,9 mm. A Hamilton
syringe with inner diameter of 810 μm was introduced to
a depth of 2, 5 mm below the brain surface, and the sphe-
roids were slowly injected and the syringe left in place for
3 min before withdrawal. The skin was closed with an
Ethilon 3-0 suture. The tumours were allowed to grow for
4-5 months, then harvested and passaged onto new ani-
mals after initiation of spheroids in vitro. Animals were
sacrificed at the onset of symptoms using CO2 and the
brains were removed. All procedures and experiments
involving animals in this study were approved by The
National Animal Research Authority and conducted
according to the European Convention for the Protection
of Vertebrates Used for Scientific purposes.
MRI Scanning
Patient MRI images were obtained by using a MRI Magne-
tom Vision Plus 1.5 T scanner (Siemens, Erlangen, Ger-
many). Animals engrafted with tissue from the initial 9
biopsies were imaged, using the same MRI combined with
a small circular finger coil [21]. Subsequently, animal
images were obtained, using a Bruker Pharmascan 7T MR
scanner (Bruker Biospin MRI GmbH, Ettlingen, Ger-
many), an axial T1 weighted MSME sequence (TR 1000
ms, TE 8.7 ms, slice thickness 1 mm, FOV 3.5 cm, matrix
size 256 × 256, 20 slices) was acquired before and after
administration of subcutaneous injection of contrast
agent (1.0 mL of 0.5 mmol/mL Omniscan; NycomedPage 2 of 13
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sequence was also acquired (TR 4200 ms, TE 36 ms, slice
thickness 1 mm, FOV 3.5 cm, and matrix size 256 × 256,
20 slices). During scanning, the animals were anesthe-
tized with 1.5% isofluorane mixed with 50% air and 50%
O2.
Histological examination and immunohistochemistry
Brains were immersion fixed in 4% formaldehyde in Dul-
becco's Phosphate-Buffered Saline for 24 h. The brains
were then embedded in paraffin, and 5 μm sections were
prepared. Every 20th section was collected for further his-
tological analysis. These sections were stained with hae-
matoxylin and eosin, and examined by a
neuropathologist under a light microscope. Representa-
tive formalin-fixed, paraffin-embedded sections from
each specimen were immunohistochemically stained with
Ki67 (MIB-1, 1:500)) or human specific nestin (1:500)
antibodies (Both Chemicon, Temecula, CA, US) by use of
the ABC method and the DCS Detection-Kit with 3, 3"-
Diaminobenzidine (DAB) and H2O2 (DCS, Hamburg,
Germany). The fraction of labelled tumour cells, defined
as the Ki67 labelling index (Ki67 LI), was assessed in 5
microscopic high power fields, appearing as "proliferative
hot-spots", which contained a high fraction of labelled
cells.
Flow Cytometry
The cell cycle distribution of the tumours was determined
by flow cytometric DNA analysis. The tumour tissue was
minced, fixed in ice-cold 70% ethanol and washed in
0.9% NaCL and then incubated at 37°C for 15 min with
0.5% pepsin (Sigma, St Lois, MO) in 0.9% NaCl solution
(pH1.5). The nuclear suspension was exposed to 100 μl of
1 mg/ml RNAse for 1 min, and then stained with propid-
ium iodide (50 mg/ml, Sigma). All samples were filtered
through a 60 mm nylon filter before analysis with a FAC-
Sort flow cytometer (Becton Dickinson, Palo Alto, CA).
Gating was performed from a two-parameter intensity
diagram (FL2 width/FL2 area) in order to exclude dou-
blets and triplets within the fluid flow. Determination of
the relative proportions of the cell cycle distribution was
obtained using the FACS software platform.
Tunnel staining
Tissue sections were de-paraffinised and the epitopes were
unmasked with protease K (20 μg/ml, Sigma) for 10 min
at room temperature. Detection of apoptotic cells was per-
formed with the terminal deoxynucleotidyltransferase
mediated nick end labelling (TUNNEL) assay according to
the manufacturer's instructions (Roche Applied Bio-
science, Manheim Germany). TUNNEL -positive cells
were visualised with DAB as chromogen, and the fraction
of Tunnel-positive cells was assessed from 5 high power
fields.
Statistics
A p-level of ≤ 0.05 was considered significant. We used the
two-tailed Student's t-test for comparison and Spearmans'
test to correlate culture time and patient age with survival
time and take rates. We used log-rank test to analyse sur-
vival data. A p-level of ≤ 0.05 was considered significant.
Results
Patient characteristics and engraftment rates
We xenografted biopsies from 29 glioma patients, of
which 25 were diagnosed with GBM, 3 patients had an
astrocytoma grade II, and one had an oligoastrocytoma
grade III (Table 1). None of the GBM patients had been
diagnosed with a lower grade lesion prior to harvesting
the GBM-biopsies, although 3 were recurrent GBMs (Case
4, 11 and 15). The age at the time of operation ranged
from 23 to 81, 18 patients were males and 11 were
females. The biopsy tissue was cut into 0.3 mm sized frag-
ments that were cultured in vitro in agar-overlay cultures as
previously described [14] and implanted as soon as sphe-
roids had formed. The culture time ranged from 3 to 67
days, while the average culture time was 18 days ± 3.3
SEM days. 25 of 29 (86%) of the biopsies formed tumour
spheroids during the first 4 weeks. Spheroids from the var-
ious biopsies were grafted onto 197 nude rats, and the
number of animals receiving tissue from the same biopsy
varied between 2 and 14. In total, 24 of the 25 GBM biop-
sies (96%) demonstrated a tumour take although at vary-
ing rates, as 137 of the 171 (80.1 ± 5.2 SEM%) animals
xenografted with GBM biopsies developed tumours. Only
one of the lower grade tumours engrafted in the nude rats
(Gemistocytic astrocytoma, WHO grade II). The average
time from implantation to onset of symptoms ranged
from 58.5 to 326.5 days, with an average of 125 ± 11.5
SEM days. The longest time interval was recorded for the
gemistocytic astrocytoma, 326.5 ± 20 SEM days. Amongst
animals xenografted with GBM biopsies harvested at the
primary operation, survival was 118 ± 9.3 SEM days.
Although survival was shorter amongst animals grafted
with recurrent GBMs (106 ± 9.9 SEM days), this difference
was not significant (p = 0.61). Culture time correlated
inversely with tumour take, but not with survival (p =
0.007 and p = 0.61, respectively). In addition, there was
no correlation between patient age vs. tumour take or sur-
vival (p = 0.69 and p = 0.78, respectively).
For 11 GBM xenografts, tumour tissue was harvested from
the rats and cultured in vitro similar to the human biop-
sies. The resulting tumour spheroids were re-implanted
into a new generation of nude rats and serially passaged
for up to 19 generations (Figure 1). Once biopsy sphe-
roids had engrafted, the take rate remained close to 100%
at all subsequent passages. The time from operation to
onset of symptoms was recorded, and became gradually
shorter with passaging (Figure 2). The difference in sur-Page 3 of 13
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cant for three of the biopsies.
Tumour histology
In order to investigate the growth pattern in the initial
phase after implantation we harvested 3 xenograft
tumours at each time point, after 3, 7 and 30 days, (Figure
3). The tumours were H/E stained and neuropathologi-
cally examined. At 3 days, the implantation site appeared
hypocellular in the center with cellular infiltration
towards the periphery accompanied by microhemor-
rhages (Figure 3A). At the second time point, a small
hypercellular tumour mass became visible at the implan-
tation site. This lesion exhibited a gradual transition to the
surrounding brain, and the haemorrhages at the periphery
were smaller (Figure 3B). After 30 days, there was no
longer a distinct lesion at the implantation site. Instead,
there was a diffuse spread of tumour cells infiltrating cor-
tical areas and white matter tracts, including the contralat-
eral hemisphere (Figure 3C). Since our previous work has
shown that the xenografted tumours express nestin we
stained the corresponding sections with a human-specific
antibody against nestin to distinguish tumour cells from
the surrounding host cells (Figure 3D-F). This showed few
immunopositive cells 3 days after implantation suggest-
ing that the majority of cells are unable to adapt in the
new environment (Figure 3D). After 7 days, more cells
were visible, suggesting ongoing proliferation, and these
cells were mostly localised to the implantation site (Figure
3E). Nestin staining of tumour sections at day 30 con-
firmed the H/E staining, demonstrating extensive tumour
cell spread (Figure 3F).
The majority of the tumours was harvested at the onset of
symptoms and was subsequently H/E stained (Figure 4).
Thus, we also used a human-specific nestin antibody to
get a precise view of tumour cell spread in the terminal
stage (Figure 4). In the first generation, the tumours grew
highly invasive with tumour cells migrating along white
matter tracts and were also invading cortical structures.
Glioma cells infiltrated the corpus callosum extensively
towards the contralateral hemisphere (Figure 4A, B, C).
Tumour cells were also observed infiltrating the cortex
(Figure 4A, D, E), subventricular zone, and the basal gan-
glia. The tumour cells were found in both hemispheres of
all the animals and in more than two cerebral lobes in
Table 1: Overview of patient characteristics for the biopsies that were engrafted, engraftment rates and survival.
Case Diagnosis Gender Age Culture time, days Tumour take, % Survival, mean days ± SEM Passage, yes/no
1 GBM f 46 4 6/6 (100) 104.5 ± 1.4 yes
2 GBM m 70 15 12/13 (92) 117.5 ± 8.6 yes
3 GBM m 31 19 4/5 (80) 169.5 ± 22.1 no
4 GBM f 31 4 7/7 (100) 97 ± 1.7 yes
5 GBM m 70 23 8/8 (100) 119.5 ± 3.5 yes
6 GBM m 45 24 2/10 (20) 93.5 ± 10.6 no
7 GBM m 47 3 7/7 (100) 126.5 ± 2.9 yes
8 GBM m 47 3 12/14 (86) 137.5 ± 5 no
9 GBM m 62 6 3/5 (60) 252 ± 1.6 no
10 GBM m 60 3 6/6 (100) 83 ± 6.6 no
11 GBM m 38 7 3/3 (100) 94.5 ± 7.7 no
12 GBM m 64 4 6/6 (100) 58.5 ± 4.3 yes
13 G-A m 49 9 0/4 (0) -- no
14 GBM f 81 4 7/8 (88) 168.5 ± 14.1 yes
15 GBM f 64 10 8/8 (100) 125.5 ± 14 yes
16 GBM f 46 17 8/10 (80) 83 ± 2.4 no
17 F-A f 38 56 0/6 (0) -- no
18 GBM m 64 26 6/7 (86) 134.5 ± 23.3 yes
19 G-A m 34 54 5/6 (83) 326.5 ± 20 no
20 GBM m 69 17 5/6 (83) 81.5 ± 3.4 yes
21 OA III f 32 7 0/10 (0) -- no
22 GBM m 61 21 0/2 (0) -- no
23 GBM f 23 67 6/7 (86) 139 ± 8.6 no
24 GBM m 60 28 6/8 (75) 126.5 ± 19 no
25 GBM f 73 25 2/4 (50) 118.0 ± 40 no
26 GBM f 66 8 5/8 (63) 111 ± 21 yes
27 GBM m 56 35 2/4 (50) 68.5 ± 2.1 no
28 GBM m 55 7 3/5 (60) 92 ± 12.9 no
29 GBM f 74 8 3/4 (75) 102 ± 6 no
Abbreviations: GBM: Glioblastoma Multiforme, G-A: Gemistocytic Astrocytoma, F-A: Fibrillary Astrocytoma, OA III: Anaplastic Astrocytoma grade 
III, f: female, m: male.Page 4 of 13
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and necroses were absent in most of the first generation
tumours. However, a subset of tumours showed these fea-
tures already in the first or second generation (data not
shown). Culture time of the biopsy spheroids did not
impact on tumour histology in these experiments as sphe-
roids cultured for both 3 days and 60 days grew highly
invasive.
Successive passaging for 3-4 generations resulted in a
gradual onset of angiogenesis and tumours that were both
invasive and highly vascular. These tumours exhibited a
typical GBM vasculature, with irregular dilated vessels,
microvascular proliferations and glomeruloid tufts (Fig-
ure 5A). Furthermore, necrotic areas with typical pseu-
dopalisading were present (Figure 5B). Altogether, the
high generation tumours fulfilled all diagnostic criteria for
GBMs. Although there was still a diffuse transition from
the tumour to the surrounding host tissue, invasion into
distant areas of the brain was less extensive compared to
low passages. Extended passaging beyond 4 generations
resulted in progressively less invasive tumours that dis-
played a more demarcated transition towards the sur-
rounding host tissue (Figure 4F, G, F, H, I and 4J).
The morphology of the tumour cells from low and high
generation GBM xenografts was compared to that of the
cells in the patient biopsies at high magnification. In the
first generation, the tumours were hypercellular, display-
ing moderate nuclear atypia as well as mitotic figures (Fig-
ure 5D, G). The nuclei of the tumour cells were mostly
round to oval and similar to those observed in patient
biopsies (Figure 5C, F). The cytoplasm of tumour cells was
eosinophilic and showed fibrillary processes, a character-
istic feature of gliomas in patients. The high generation
tumours were highly cellular and the nuclei of tumour
cells became more polymorphic and hyperchromatic
compared to the first generation and patient-derived
tumours. They often contained prominent nucleoli. The
Experimental designFigu e 1
Experimental design. Biopsy tissues from human gliomas are minced into small fragments that are subsequently cultured in 
medium. The tumour fragments remodel and form small tumour spheroids, usually within 1-2 weeks. These spheroids are ster-
eotactically implanted in the nude rat brain, and form xenograft tumours (1st or low generation) that are harvested and proc-
essed similarly to the biopsy tissue. The resulting spheroids are passaged onto a new generation of rats and the previous steps 
can be repeated to passage the tumour for several generations.
Survival as a function of tumour passaging in vivoFigure 2
Survival as a function of tumour passaging in vivo. 
Shown are survival data for nude rats xenografted with 
GBM-biopsy tissue that were passaged in vivo for several gen-
erations. The patient number refers to cases listed in Table 1. 
For rats xenografted with tumour tissue from patient 20, 
survival was significantly shorter with passaging for 3 genera-
tions (p = 0.0029). For rats xenografted with tissue from 
patient 15, survival also decreased with passaging, although 
this was not significant (p = 0.69).Page 5 of 13
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ure 5E, H). In addition, there were more mitotic figures,
which lead us to specifically assess the growth kinetics of
these tumours (Figure 6).
Thus, low generation tumours recapitulated the invasive
growth of parental tumours and showed a similar cellular
morphology and proliferation. In contrast, high genera-
tion tumours demonstrated all hallmarks of GBM growth,
but the cells appeared more transformed and the mitotic
index was higher compared to their parental tumours.
Assessment of tumour growth by flow cytometry and 
immunohistochemistry
Since the overall tumour growth reflects the net balance
between cell proliferation and death, we specifically
assessed these parameters (Figure 6). Flow cytometry anal-
ysis showed that the S-phase fraction increased with pas-
saging (Figure 6A). While the S-phase fraction in 1st
generation tumours was 12.4% and close to the value esti-
mated for the human biopsy of 11.9%, the S-phase frac-
tion in the high generation tumours was 19.8%. Likewise,
there was no significant differences in Ki67 labelling index
(LI) between the low generation and the human biopsy
derived tumours (26% and 20%, respectively, Figure 6B
and 6C). However, LI was significantly higher in high gen-
eration tumours (49%) compared to the human biopsies
and the low generation tumours (p = 0.0003 and p =
0.012, respectively). Thus, these findings corroborated the
flow cytometry analysis to provide evident for greater cel-
lular proliferation in the high generation tumours.
Moreover, we performed tunnel staining to compare
apoptosis in the different tumour types (Figure 6B and
6D). Here, cell death levels were highest in the human
tumour samples and showed a significant decline with
passaging (p = 0.0008 and p = 0.037, respectively).
MRI assessment of tumour growth
The animals were monitored at various time points during
the in vivo passaging by MRI using standard dynamic con-
trast enhanced clinical sequences. These included T1 with
and without contrast agent injection for delineation of
tumour volumes, as well as assessment of blood brain bar-
rier function (Table 2 and Figure 7). T2 sequences were
employed for visualising oedema and accumulation of
cerebral spinal fluid (Figure 7). Longitudinal MRI revealed
that the tumour growth characteristics were highly repro-
Xenograft tumour histology in initial stages of tumour growthFigure 3
Xenograft tumour histology in initial stages of tumour growth. Growth of 1st generation tumours 3 (A), 7 (B) and 10 
days (C) following implantation of patient biopsy spheroids, H/E staining. Shown are the implantation site (A, B) and contralat-
eral hemisphere (C). Corresponding sections were also stained with a human-specific antibody against nestin (D, E, F). Scale 
bars = 100 μmPage 6 of 13
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lesions appeared poorly delineated on T1 sequences,
while secondary changes such as hydrocephalus and shift
of midline structures (Table 2 and Figure 7B) indicated
the presence of an expansive lesion. Contrast enhance-
ment was usually not evident, while small focal regions of
contrast leakage were detected in some tumours. A diffuse
high signal intensity area was visualised with T2
sequences 8-10 weeks post implantation that increased
gradually in size to occupy both hemispheres at the termi-
nal stages. MRI scans of tumours from subsequent gener-
ations revealed a gradual onset of contrast enhancement
up to 4th or 5th generation, after which the tumours
remained strongly contrast enhancing. However, with fur-
ther passaging the tumours gradually displayed less infil-
trative growth and became more circumscribed. Thus,
passaging in vivo provided different combinations of inva-
sive and vascular tumour phenotypes; 1) non-angiogenic
and invasive tumours, 2) angiogenic and invasive
tumours and 3) angiogenic and poorly invasive tumours
(Figure 7B).
Discussion
Outcome and treatment has improved only marginally
over the last decades for GBMs [22], and reflect a limited
understanding of the mechanisms that regulate their bio-
Xenograft tumour histology in early and late generationsFigure 4
Xenograft tumour histology in early and late generations. Growth of 1st (A, B, C, D, E) and 10th generation (F, G, H, I, 
J) tumours in different areas of the nude rat brain. Corpus Callosum; H/E staining (B, G) and nestin staining (C, H), Cortex; 
H&E (D, I) and nestin (E, J). Scale bars = 250 μm.Page 7 of 13
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models that reliably mimic their invasive and vascular
growth. Transgenic brain tumour models, involve germ-
line or somatic genetic modifications that predispose ani-
mals to developing CNS tumours [23-25]. However,
whereas these models have a limited number of defined
genetic changes, human brain tumours are characterised
by multiple genetic aberrations. Alternatively, tumour
development can be induced by carcinogen exposure or
established by implantation of [26,27] or xenogeneic [26]
cancer cells or tumour biopsies [19,20]. While cell line
based models often fail to mimic essential characteristics
of brain tumours [4], some studies have reported growth
of highly infiltrative tumours, following the implantation
of human glioma biopsies in the nude rat brain [4,19,20].
Sakaria et al reported that the parent tumour's EGFR
amplification status was preserved through subcutaneous
passaging of the glioblastoma xenografts in nude mice
[28]. Moreover, cell suspensions established from short-
term in vitro cultures of flank xenograft tumours could
subsequently be xenografted orthotopically. They success-
fully applied this approach to investigate how EGFR
amplification status impacted on response to radiation
therapy. Here, we report another approach passaging
Comparison of tumour cell morphology between patient and xenograft tumoursFigure 5
Comparison of tumour cell morphology between patient and xenograft tumours. (A) Glomeruloid microvascular 
proliferations in a high generation tumour, H&E staining. (B) Palisading necrosis in a high generation tumour, H&E staining. 
Patient biopsies (C, F) with corresponding low (D, G) and high generation xenografts (E, H), H&E staining. Scale bars = 100 μmPage 8 of 13
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host. Since tumour-host interactions are organ-specific,
we believe that orthotopic passaging throughout the
experiment avoids adaption towards a foreign niche, such
as subcutaneous tissue. Furthermore, the somewhat larger
size of the rat brain makes it possible to conduct certain
experiments, such as convection-enhanced delivery from
subcutaneously implanted pumps, which are not easily
performed in mice. Moreover, we implant spheroids initi-
ated from the tumours which also contain ECM compo-
nents and stromal cells within the tumour environment,
whereas this stromal compartment is disrupted when cell
suspensions are used. Previously, we have also shown that
first generation tumours derived from GBM biopsies often
exhibit angiogenesis-independent growth while passaging
is accompanied by the onset of angiogenesis, producing
highly vascular tumours [20,29,30]. Moreover, gene
expression profiling and protein arrays demonstrated that
this phenotypic shift coincided with alterations in signal-
ling pathways [20]. Whereas components of the Wnt,
PI3K, and NF-kβ signalling pathways were overexpressed
in the invasive first-generation tumours compared with
the high-generation tumours, the Ras signalling pathway
was up-regulated in the high generation tumours.
However, although this model mimics essential brain
tumour phenotypes, its implementation require that it
provides sufficiently reproducible data as well. Whereas
many aspects related to the use of cancer cell lines can be
standardised, outcome parameters such as tumour growth
and survival data from cell line experiments may still vary.
In our series, average survival was 118 days, whereas the
Higher growth rates after passaging are mediated by increased tumour cell proliferation and reduced tumour cell deathFi ure 6
Higher growth rates after passaging are mediated by increased tumour cell proliferation and reduced tumour 
cell death. S-phase fraction in a patient biopsy and the resulting xenograft tumours at various stages of passaging (A). Ki67 and 
Tunnel staining of corresponding tumour biopsies (B), with quantification of their labelling indexes (C) and (D), respectively. 
Scale bars = 100 μm.Page 9 of 13
(page number not for citation purposes)
BMC Cancer 2009, 9:465 http://www.biomedcentral.com/1471-2407/9/465
Page 10 of 13
(page number not for citation purposes)
MRI monitoring shows that brain tumour growth can be standardised and that the phenotypes are modulated with passaging in vivoFigure 7
MRI monitoring shows that brain tumour growth can be standardised and that the phenotypes are modulated 
with passaging in vivo. Coronary MRI scans showing tumour growth in four rats grafted with tissue from the same patient 
biopsy. Shown are T2 sequences at 3 different time points as indicated, while the right column present T1 images after adminis-
tering contrast agent (A). MRI scans demonstrating different brain tumour phenotypes (B), displaying angiogenic and invasive 
growth as indicated (bottom). Corresponding H/E stained tumour sections are shown below the MRI panels. Extended passag-
ing provide 3 distinct phenotypes that represent different combinations of invasive and angiogenic growth patterns.
BMC Cancer 2009, 9:465 http://www.biomedcentral.com/1471-2407/9/465average standard error of the mean (SEM) was 9.3 days,
which compares well to other cell line based studies [31-
33]. Moreover, 24 of 25 (96%) GBM biopsies produced
tumours in 137 of 171 (80%) nude rats. These findings
are similar to a previous smaller study in which 5 of 6
(83%) of the GBM biopsies produced tumours in 38 of 47
(81%) nude rats [19]. This is also in line with numerous
studies using primary biopsies from other subtypes that
provide high tumour take rates [3,15-18,34-37]. The low
take rates we observed with biopsies from grade II and III
tumours may be due to a lack of adaptability to the rat
brain environment. However, while grade II gliomas may
appear radiologically unchanged for several years in the
patient, the life span of nude rats is in the range of 1,5 -2
years under specific pathogen free conditions [38]. There-
fore, the low take rates may simply reflect that the time
required to develop clinically manifest tumours from low
grade glioma biopsies exceeded the life span of the hosts.
Although the number of lower grade tumours was small
in this study, these findings still question the use of this
model system to study such tumours. In summary, these
findings demonstrate that the large majority of GBMs
engraft in nude rats with a high take rate, and mediate a
reproducible disease course if experimental parameters
are standardised.
Furthermore, MRI provided information about essential
aspects of tumour growth such as tumour volume, con-
trast enhancement, invasiveness, shift of midline struc-
tures, surrounding oedema as well as hydrocephalus.
Based on these features, MRI reliably distinguished the
different tumour phenotypes identified by histological
examination. Thus, MRI with clinical sequences can be
used in used in conjunction with this model to distin-
guish the different tumour phenotypes by and monitor
growth by imaging in vivo.
Histological analysis at day 3 after implantation revealed
that the implantation site contained few cells in the cen-
tre, but with cellular infiltration and microhemorrhages at
the periphery. This picture may reflect initial reactive
changes following implantation, where most tumour cells
fail to adapt to the new environment and die. Accordingly,
the small tumour visible in the implantation site after 7
days reflects a regrowth of the tumour cells that survive
the initial phase. The extensive spread of tumour cells
after 30 days suggest that activation of pro-invasive pro-
grams is an integral part of the adaptive behaviour needed
to sustain growth during the early phases.
In the late stages, at the onset of symptoms, the first gen-
eration tumours recapitulated the invasive features of the
parent tumours like previously reported, but were largely
devoid of angiogenesis and necrotic areas. Moreover,
tumour cells were found in more than two cerebral lobes
and in the contralateral hemisphere. The morphology of
tumour cells at high magnification was similar to that
observed in patient biopsies.
In contrast, high generation tumours fulfilled all diagnos-
tic criteria of human GBMs, but grew less invasive. The
tumours had a higher cell density and the tumour cells
displayed a more malignant phenotype compared to low
generation tumours and patient biopsies with large, poly-
morphic nuclei and a less fibrillary, but more circum-
scribed cytoplasm. Immunohistochemistry also showed
that the Ki67 labelling was higher in the tumour
xenografts than in the patient biopsies, and increased with
passaging. Moreover, tunnel analyses shows that cell
death rates declined with propagation in vivo, pointing to
an additional mechanism for the increased overall growth
rates that we observed in higher generation tumours.
Thus, the faster growing high generation tumours result
both from increased gain due to higher cell proliferation,
as well as reduced cell loss due to less apoptosis.
It is an important question whether this progression seen
in the rat is also the course of primary GBMs in the
patients. It is conceivable that the initial GBM in the
patient is growing as an invasive lesion without angiogen-
esis. GBMs are mostly diagnosed at late stages, when the
tumours have reached a certain size causing symptoms
and changes in MRI due to mass effects, angiogenesis with
breakdown of the blood-brain-barrier and necrosis. Thus,
early stages are not easily detectable on contrast enhanced
sequences, due to lack of these features. While we previ-
ously demonstrated that passaging the tumours for 4-5
generations was accompanied by an onset of angiogenesis
[20], this study includes biopsies that have been passaged
for up to 19 generations. MRI imaging of the animals and
histological examination of the tumours revealed that
extended passaging was accompanied by a gradual loss of
Table 2: MRI characteristics of xenograft tumours in low and high generation.
Radiological Feature Low Generation High Generation
Edema in tumour mass 15/15 8/8
Edema in contralateral hemisphere 15/15 3/8
Hydrocephalus 14/15 8/8
Contrast enhancement (T1) 4/15 8/8Page 11 of 13
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a model for modulating essential brain tumour pheno-
types. Since these different phenotypes can be derived
from the same patient, variation in genetic background
due to inter-individual differences is eliminated. Further,
systematic comparisons of angiogenic and non-ang-
iogenic tumours that are both invasive and otherwise sim-
ilar may help identify genes and proteins critical to the
onset and maintenance of brain tumour angiogenesis.
Using the same strategy on invasive and non-invasive
tumours can help to identify invasion-related genes and
proteins [29]. We therefore believe this model provides a
powerful tool do dissect mechanisms that mediate angio-
genesis and invasive growth.
Conclusions
In conclusion, our data demonstrate that xenograft
tumours representative of the parent tumour can be estab-
lished in nude rats with a high take rate and a reproduci-
ble disease course. Furthermore, MRI using standard
clinical sequences provides useful information regarding
critical GBM phenotypes involved in tumour progression.
Studies at various time points as well as at different stages
of passaging suggest that the adaptive behaviour of these
tumours display to main phases; one initial phase relying
on pro-invasive programmes, and one later stage charac-
terised by angiogenesis, increased cell proliferation and
reduced apoptosis, leading to increased overall growth
rates. In humans, this model may have a special relevance
to early stages of tumour growth, prior to onset of symp-
toms and diagnosis.
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